Assuntos
Síndrome de Alagille/genética , Opacidade da Córnea/genética , Receptor Notch2/genética , Síndrome de Alagille/diagnóstico , Síndrome de Alagille/patologia , Criança , Opacidade da Córnea/diagnóstico por imagem , Diagnóstico Tardio , Fácies , Feminino , Estudos de Associação Genética , Humanos , Mutação de Sentido Incorreto , Mutação Puntual , Estenose da Valva Pulmonar/genética , Lâmpada de Fenda , Vértebras Torácicas/anormalidades , Ácido Ursodesoxicólico/uso terapêutico , Vitamina D/uso terapêuticoRESUMO
OBJECTIVE: CSF levels of inositol have been reported to be lower than normal in depressed subjects. The authors administered inositol to depressed patients in a double-blind, controlled trial. METHOD: Under double-blind conditions, 12 g/day of inositol (N = 13) or placebo (N = 15) was administered to depressed patients for 4 weeks. RESULTS: The overall improvement in scores on the Hamilton Depression Rating Scale was significantly greater for inositol than for placebo at week 4. No changes were noted in hematology or in kidney or liver function. CONCLUSIONS: This may be the first use of the precursor strategy for a second messenger rather than a neurotransmitter in treating depression. Although inositol had a significant antidepressant effect in this study, replication is crucial.
Assuntos
Transtorno Depressivo/tratamento farmacológico , Inositol/uso terapêutico , Adulto , Idoso , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Transtorno Depressivo/psicologia , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Placebos , Escalas de Graduação Psiquiátrica , Resultado do TratamentoRESUMO
During a follow-up period of 23-40 months, 7 regular blood donors had persistently, and 4 had intermittently indeterminate anti-p24gag reactivity in human immunodeficiency virus (HIV)-1 Western Blot. Serological testing and viral cultures revealed that these donors had no signs of infection for HIV-1, HIV-2, human T-cell lymphotropic virus (HTLV)-4, and HTLV-1. Extensive interviewing and physical examination of these donors revealed neither risk factors, nor signs of HIV infection in the tested donors. Ten recipients, who were transfused with blood products from 6 of these 11 anti-p24gag-positive donors, were traced back. Six months after transfusion, no serological or clinical signs of HIV-1, HIV-2, or HTLV-1 infection were observed in these patients. It is concluded that blood donors with persistent or intermittent anti-p24gag reactivity in HIV-1 Western Blot, without development of antibodies to other HIV-encoded proteins in later blood samples, do not transmit the described retroviruses to transfused patients.